These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 4150175)
21. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)]. Chéreau I; Gorwood P; Mouchabac S Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186 [No Abstract] [Full Text] [Related]
22. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP]. Buis C; Gourion D; Vaiva G Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185 [No Abstract] [Full Text] [Related]
23. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?]. Dassa D; Lacambre M; Vacheron MN Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179 [No Abstract] [Full Text] [Related]
24. Impace of depot neuroleptics on psychiatry. Corbett L Minn Med; 1979 Feb; 62(2):97-100. PubMed ID: 34788 [No Abstract] [Full Text] [Related]
25. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). What are the limiting factors in resort to an APAP and how to overcome them]. Canceil O; Limosin F; Passerieux C Encephale; 2009 Jan; Suppl 3():S101-7. PubMed ID: 19268178 [No Abstract] [Full Text] [Related]
29. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. Dencker SJ J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744 [TBL] [Abstract][Full Text] [Related]
30. Long-acting phenothiazines in schizophrenia. Freeman H Lancet; 1972 Dec; 2(7789):1245-6. PubMed ID: 4117727 [No Abstract] [Full Text] [Related]
31. [7 years of experience with delayed action neuroleptics]. Noguera Hosta R; Rendueles de Olmedo G Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1978; 6(3):293-8. PubMed ID: 31066 [No Abstract] [Full Text] [Related]
32. [Is depot formulation a long-term optimal treatment option?]. Musch A Med Monatsschr Pharm; 2005 Nov; 28(11):414-6. PubMed ID: 16309031 [No Abstract] [Full Text] [Related]
33. [Current questions on the use of neuroleptics in everyday practice]. Perényi A; Frecska E Orv Hetil; 1984 Dec; 125(49):2985-8, 2991. PubMed ID: 6151164 [No Abstract] [Full Text] [Related]
34. [Importance of pharmacotherapy in the rehabilitation of schizophrenic patients]. Wojdysławska I Psychiatr Pol; 1977; 11(6):683-8. PubMed ID: 25450 [No Abstract] [Full Text] [Related]
35. [Depot neuroleptics in social psychiatric practice]. Pruss U; Rose HK; Zechner A Psychiatr Prax; 1984 Jul; 11(4):101-8. PubMed ID: 6148764 [TBL] [Abstract][Full Text] [Related]
36. A long-term pilot study of pipothiazine palmitate in chronic schizophrenia. Villeneuve A; Pires A; Jus A; Lachance R; Drolet A Curr Ther Res Clin Exp; 1972 Nov; 14(11):696-706. PubMed ID: 4404626 [No Abstract] [Full Text] [Related]
37. [Schizophrenia: prophylaxis prevents recurrence. Low dose depot neuroleptics--an exit from the "revolving door" psychiatry]. Fortschr Med Suppl; 1993; 147():1-15. PubMed ID: 9260317 [No Abstract] [Full Text] [Related]